{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:03:30Z","timestamp":1787425410847,"version":"build-2736575974"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00198-022-06617-2","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:46:07Z","timestamp":1669902367000},"page":"421-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Appropriate dosing of burosumab in tumor-induced osteomalacia"],"prefix":"10.1007","volume":"34","author":[{"given":"Luciano","family":"Colangelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Riminucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-4509","authenticated-orcid":false,"given":"Alessandro","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"6617_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-022-06516-6","volume":"4","author":"C Crotti","year":"2022","unstructured":"Crotti C, Zucchi F, Alfieri C, Caporali R, Varenna M (2022) Long-term use of burosumab for the treatment of tumor-induced osteomalacia. Osteoporos Int 4:1\u20136. https:\/\/doi.org\/10.1007\/s00198-022-06516-6","journal-title":"Osteoporos Int"},{"key":"6617_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur SM et al (2021) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 36:627\u2013635. https:\/\/doi.org\/10.1002\/jbmr.4233","journal-title":"J Bone Miner Res"},{"key":"6617_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Imanishi Y et al (2021) Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res 36:262\u2013270. https:\/\/doi.org\/10.1002\/jbmr.4184","journal-title":"J Bone Miner Res"},{"key":"6617_CR4","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/jbmr.4318","volume":"36","author":"IR Hartley","year":"2021","unstructured":"Hartley IR, Collins MT (2021) Burosumab for tumor-induced osteomalacia: not enough of a good thing. J Bone Miner Res 36:2453\u20132454. https:\/\/doi.org\/10.1002\/jbmr.4318","journal-title":"J Bone Miner Res"},{"key":"6617_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383\u20131393. https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06617-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T17:46:33Z","timestamp":1674495993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06617-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6617"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06617-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Salvatore Minisola served as a speaker for Abiogen, Bruno Farmaceutici, Diasorin, Kyowa Kirin, UCB. He also served in the advisory board of Eli Lilly, Kyowa Kirin, UCB. All other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}